EMA has recommended granting a marketing authorisation in the European Union for the first treatment that can be given orally to patients with certain types of spinal muscular atrophy (SMA), a rare and often fatal genetic disease that causes muscle weakness and progressive loss of movement.
Evrysdi is indicated for the treatment of 5q SMA in patients 2 months of age and older, with a clinical diagnosis of Type 1, Type 2 or Type 3 SMA or with one to four SMN2 copies.
Spinal muscular atrophy is an inherited disease usually diagnosed in the first year of life that affects the motor neurons (neurons from the brain and spinal cord that control muscle movements). Patients with the disease lack a protein called ‘survival motor neuron’ (SMN), which causes the motor neurons to deteriorate and eventually die. This is a long-term debilitating and life-threatening disease because it causes breathing problems and muscle wasting that worsens over time.
The SMN protein can be made by two genes, SMN1 and SMN2. Patients with spinal muscular atrophy lack a working SMN1 gene but have at least one copy of the SMN2 gene, which mostly produces a short SMN protein that does not work as well as a full-length protein.
Risdiplam, the active substance of Evrysdi, has shown that it can enable the SMN2 gene to produce a full-length SMN protein, which is able to work normally. This is expected to increase survival of motor neurons and reduce symptoms of the disease.
Although a number of treatment options have become available over recent years, they all require frequent clinic visits or invasive procedures. During the COVID-19 pandemic these treatments have become more difficult to access due to measures to promote physical distancing and changes in hospital priorities that have postponed elective procedures.
New therapies with easier routes of administration are needed to help patients with this life-long chronic disease to adhere to their treatment and get the full benefit from it.
Evrysdi has been developed as a non-invasive oral treatment that can be used at home. It was accepted into PRIME, a support scheme EMA developed for promising new medicines that address an unmet medical need. Representatives of patient organisations were also consulted during the assessment of benefits and risks of Evrysdi to bring their unique real-life perspective and ensure that patients’ needs are taken into account in the regulatory decision-making process. EMA’s human medicines committee (CHMP) reviewed the application for marketing authorisation under an accelerated timetable to enable faster patient access to this medicine.
Related Posts
31 July 2024
Meet our AI- driven robot
We are more than proud to announce that, through a tight collaboration with SUPSI (Università della Svizzera Italiana) and our partner KeepOne Swiss Vision Technology, we have developed the…
9 January 2024
Please join us in congratulating Fabio for his first successful year in Elixi!
Let's put a face to a name! Let us introduce you to one of the "pillars" of our organisation, our Head of Quality and Medical department, the mighty Fabio Macchi! Fabio joined us exactly…
13 September 2023
Come and meet us at Expopharm 2023! 27 -30 September in DÜSSELDORF.
Come and meet us at Expopharm 2023! 27 -30 September in DÜSSELDORF. Our colleagues Luca Schincaglia and Marco Ferrario will be there and happy to chat with you! #expopharm2023 #expopharm…